An Alzheimer's disease vaccine shows safety and immune response

Chinanews.
com, Beijing, June 15 (Reporter Sun Zifa) Springer Nature’s professional academic journal "Nature-Aging" recently published a medical research paper saying that researchers are targeting Alzheimer’s disease commonly known as Alzheimer’s.
The results of phase 2 clinical trials of a vaccine developed by AD) show that this vaccine named AADvac1 is safe and can induce an immune response in patients with mild Alzheimer's disease
.

However, the paper also reminded that researchers could not detect the specific impact of the AADvac1 vaccine on patients' cognitive decline
.

The paper introduced that the toxic form of tau protein would accumulate and spread in the brains of patients with Alzheimer's disease, which is also a pathological feature of the disease
.

Corresponding author of the paper, Petr Novak of AXON Neuroscience Customer Relationship Management Service in Bratislava, Slovakia, and colleagues conducted a phase 2 randomized placebo-controlled trial, enrolling 196 mild Alz Patients with Haimer disease (mean age 71.
4 years; 45.
1% male; 100% white)
.

The authors of the paper generally concluded that although patients have a good tolerance to AADvac1 and can produce an immune response to tau protein, the vaccine cannot produce statistically significant cognitive benefits.
This may be due to the lack of tau protein pathology in some patients.
Performance, or because the sample size of the study is small
.